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b a c k g r o u n d : Glycohemoglobin (GHB), reported as 
hemoglobin (Hb) A lt, is a marker o f long-term glyce- 
mic control in patients with diabetes and is directly 
related to risk for diabetic complications. HbE and 
HbD are the second and fourth most common Hb vari­
ants worldwide. We investigated the accuracy o f HbAlt 
measurement in the presence o f HbE and/or HbD 
traits.
m e t h o d s : We evaluated 23 HbAlt methods; 9 were im­
munoassay methods, 10 were ion-exchange HPLC 
methods, and 4 were capillary electrophoresis, affinity 
chromatography, or enzymatic methods. An overall 
test o f coincidence o f 2 least-squares linear regression 
lines was performed to determine whether the presence 
of HbE or HbD traits caused a statistically significant 
difference from HbAA results relative to the boronate 
affinity HPLC comparative method. Deming regres­
sion analysis was performed to determine whether the 
presence o f these traits produced a clinically significant 
effect on HbAlt results with the use o f ±10%  relative 
bias at 6% and 9% HbAlt as evaluation limits.
r e s u l t s : Statistically significant differences were found 
in more than half o f the methods tested. Only 22% and 
13% showed clinically significant interference for HbE 
and HbD traits, respectively.
c o n c l u s io n s : Some current HbAlt methods show clin­
ically significant interferences with samples containing 
HbE or HbD traits. To avoid reporting o f inaccurate 
results, ion-exchange chromatograms must be care­
fully examined to identify possible interference from 
these Hb variants. For some methods, manufacturers’
instructions do not provide adequate information for 
making correct decisions about reporting results.
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Glycohemoglobin (GHB),8 reported as hemoglobin 
(Hb) A lt, is a marker o f long-term glycemic control in 
patients with diabetes mellitus. The Diabetes Control 
and Complications Trial (DCCT) and the United 
Kingdom Prospective Diabetes Study demonstrated 
conclusively that risks for complications are directly 
related to glycemic control, as measured by HbAlt 
(1, 2 ). Many diabetes organizations worldwide recom­
mend specific HbAlt targets in terms o f DCCT/United 
Kingdom Prospective Diabetes Study HbAlt. The Na­
tional Glycohemoglobin Standardization Program was 
established to standardize GHB/HbAlt results so that 
clinical laboratory results are comparable to those re­
ported by the DCCT. However, the accuracy o f several 
HbAlt methods can be adversely affected by the pres­
ence o f Hb variants (3 ), and the National Glycohemo­
globin Standardization Program does not include eval­
uation o f interferences as part o f the certification 
program. The most common Hb variants worldwide 
are HbS, HbE, HbC, and HbD. Unlike HbS and HbC 
traits, for which most o f the commonly used HbAlt 
methods have already been, and continue to be, evalu­
ated ( 4 -6 )  few data are available on the accuracy of 
HbAlt measurement in the presence of HbE or HbD 
traits. Therefore we evaluated the effects o f HbE and 
HbD trait on 23 commercial GHB methods using the 
Primus boronate affinity HPLC assay (ultra2) as the 
comparison method.
HbE contains a substitution o f lysine for glutamic 
acid at position 26 o f the j3-globin chain. HbE is the
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second most prevalent Hb variant worldwide and is 
found primarily in people from Southeast Asia; preva­
lence is 30%-40% in some parts o f Thailand, Cambo­
dia, and Laos (7 ). Owing to an influx o f immigrants 
from Southeast Asia in recent years, HbE is now en­
countered quite commonly in the US. HbD Punjab 
(also called HbD Los Angeles), hereafter referred to as 
HbD, contains a substitution of glutamine for glutamic 
acid at position 121 o f the j3-globin chain. HbD Punjab 
is found most commonly in the Punjab region of India 
(2%-3% prevalence in Sikhs in Punjab) and is also en­
countered in the US (8).
Materials and Methods
SAMPLES
This study was approved by the ethics review commit­
tee at DynaLIFEDX in Edmonton, Canada, where the 
samples originated. Whole blood samples from indi­
viduals homozygous for HbA (n =  49) and for HbE 
or HbD trait (HbAE, HbAD) (n =  42 for each trait) 
were collected in EDTA-containing tubes. After rou­
tine clinical testing had been completed, the samples 
previously identified as having HbD Punjab or HbE 
traits by use of the Bio-Rad Beta Thalassemia HPLC 
system and Sebia Hydrasys electrophoresis at both al­
kaline and acid pH were shipped on cold packs to the 
Diabetes Diagnostic Laboratory at the University of 
Missouri (Columbia, MO). Several small aliquots were 
made from each sample and stored at — 70 °C until they 
were shipped on dry ice to various sites for analysis.
Assay methods. Samples were analyzed by the follow­
ing instruments/methods grouped by method type: 
Immunoassay methods used were AlcNow (Bayer/ 
Metrika), Synchron UniCel DxC (Beckman Coulter), 
Dimension RxL (Dade Behring), Au400 (Olympus Di­
agnostics), Vitros (Ortho-Clinical Diagnostics), HbAlc 
(PointeScientific) on Modular?, Integra800Gen2and 
Tina-quant on Hitachi 917 (Roche Diagnostics), and 
DCA2000 (Siemens Medical Solutions). Ion-exchange 
HPLC methods used were D-10 (short and extended 
programs), Variant, Variant II Turbo, and Variant II 
NU (Bio-Rad Laboratories); HA8160 Diabetes mode 
and HA8160 Thalassemia Program (TP) mode (A. 
Menarini Diagnostics); and A le 2.2 Plus, G7 (Variant 
Analysis Mode), and G8 (Variant Analysis Mode) 
(Tosoh Biosciences). Capillary electrophoresis, en­
zyme, and boronate affinity HPLC methods used were 
CE on PACE 5000 (Analis, Beckman Coulter), Direct 
Enzymatic HbAlc (Diazyme Laboratories) on Modu­
lar P (Roche Diagnostics), Afinion (Axis-Shield), and 
PDQ (Primus Diagnostics).
The Primus ultra2 HPLC method was used as the 
comparison method because results from boronate af­
finity chromatography are not expected to be influ­
enced by the presence of Hb variants (9 -1 3 ). The G7, 
Tina-quant on Hitachi 917, ultra2, CE, and HA8160 
diabetes modes are National Glycohemoglobin Stan­
dardization Program Secondary Reference Laboratory 
(SRL) methods (SRL7, SRL4, SRL3, ESRL3, and ESRL7, 
respectively)
Data Analysis. For each test method, results obtained 
for each type o f sample (homozygous HbA, HbE trait, 
and HbD trait) were compared to those we obtained 
using the ultra2 comparison method. An overall test of 
coincidence o f 2 least-squares linear regression lines 
was performed using SAS software (SAS Institute) to 
determine whether the presence o f HbE or HbD trait 
caused a statistically significant difference (P <  0.01) in 
results relative to the comparison method. Deming re­
gression analysis was performed to determine whether 
the presence o f HbE or HbD trait produced a clinically 
significant effect on HbAlc results. Given recommen­
dations by the American Diabetes Association o f an 
upper reference limit o f 6%, the American Diabetes 
Association goal o f 7%, and the DCCT conventional 
group mean HbAlc of approximately 9%, we chose 
HbAlc evaluation limits of 6% and 9%. After correcting 
for possible calibration bias by comparing results from 
the homozygous HbA sample group, we evaluated 
method bias due to the presence o f HbE or HbD trait, 
with a clinically significant difference being >10%  rel­
ative bias at 6% and 9% HbAlc (i.e., 0.6% at 6% HbAlc 
and 0.9% at 9% HbAlc).
Results
Box plots for each group of samples and for each 
method, with indications o f both statistical and clinical 
significance are shown in Fig. 1. Although statistically 
significant differences were found in more than half of 
the methods tested, only 5 o f 23 and 3 o f 23 showed 
clinically significant interferences for HbE and HbD 
traits, respectively. Table 1 lists the differences at 6% 
and 9% HbAlc for each variant and for each method. 
There were no clinically significant differences seen for 
either HbE or HbD traits for any o f the immunoassay 
methods tested, or for the PDQ, Afinion, Enzymatic 
method, CE method, Variant II NU, or D-10 short and 
extended programs. In addition, there were no clini­
cally significant differences seen for HbD trait for the 
2.2 Plus, G7, or G8. There were no clinically significant 
differences seen for the HbE trait for the Variant and 
the HA-8160 TP mode. The Variant II Turbo showed 
clinically significant interference from both HbE and 
HbD traits, as did the Menarini HA8160 diabetes 
mode. The HA-8160 TP mode does not quantify HbAlc 
in the presence o f HbD trait.
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Fig. 1. Box-plots summarizing the absolute differences (%HbA1c) between each test method and the comparison 
method for each Hb phenotype.
The horizontal line in each box is the median difference between the test and comparison methods. The upper and lower limits 
of each box correspond to the 25th and 75th percentile of the differences, respectively. The highest and lowest horizontal bars 
represent the minimum and maximum differences between the test and comparison methods. Differences from HbAA that are 
statistically significant are indicated (#) below each bar where appropriate; clinically significant differences are indicated (*) 
above each bar where appropriate. Menarini HA-8160 TP mode results are not shown for HbD trait since HbA1c results are not 
quantified in these samples.
In addition to the actual bias in the HbAlc result 
caused by the presence o f these variant Hbs, it is impor­
tant that any unacceptable results are detected and not 
reported. Fortunately, we found that results from sam­
ples with HbE and HbD traits do not show interference 
with HbAlc measurement by the immunoassay, enzy­
matic, and boronate affinity methods that were evalu­
ated, because Hb variants are not discernable with 
these methods. It is not surprising that HbE and HbD 
traits do not interfere with immunoassay methods, 
given that the amino acid substitutions are far from the 
N-terminus o f the j3 chain where HbAlc glycation and 
antibody binding occur. These results were consistent 
with a previous report (12).
In cases in which ion-exchange methods show 
clinically significant interferences, it is important to 
know whether following manufacturer instructions 
would prevent the reporting o f unacceptable results. 
Unfortunately, some manufacturer instructions for ac­
ceptance o f results by ion-exchange methods are not 
clearly stated, and some manufacturers do not provide 
sample chromatograms. Examples of chromatograms
from such methods with clinically unacceptable results 
are shown in Supplemental Figs. 1 -4  in the Data Sup­
plement that accompanies the online version of this 
article at http://www.clinchem.org/content/vol54/issue8.
For the Tosoh 2.2 Plus, the manufacturer states 
that it is acceptable to report an “Hb Var” peak after 
HbA0; this would include a peak for the HbD trait. Our 
data confirm the acceptability of these manufacturer 
instructions. If there is an unidentifiable peak before the 
A() peak (e.g., POO, P01), the result is not reportable; this 
is the case for HbE trait, and indeed our data show 
nonreportable results for HbAE. For the Tosoh G7, the 
manufacturer instructions say that any abnormal peak 
before HbA0 will cause erroneous HbAlc results; this 
includes a peak for the HbE trait. Our results confirm 
that such abnormal peaks are indeed not reportable. 
Because the HbD peak appears after the HbA0 peak, 
results showing this peak should be reportable; our 
study data confirm this. For the G8, the manufacturer 
instructions state that the HbAlc is reportable for HbD 
trait because the variant peak and POO peaks elute after 
the AO and their sum is not >55%. HbAE is stated to be
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Table 1. Mean differences from the comparison method for samples containing either HbE or HbD trait.3
HbE trait HbD trait
Manufacturer*1 Method n 6% HbA1c 9% HbA1c n 6% HbA1c 9% HbA1c
Immunoassay
Bayer/Metrika AlcNow 42 -0.13 -0.18 41 -0.01 0.17
Beckman Synchron DxC 42 -0.06 -0.16 42 -0.02 0.05
Dade Behring HbA1c on Dimension RxL 42 -0.17 -0.28 42 -0.08 -0.10
Olympus HbA1c on Au400 42 0.01 0.22 42 0.06 0.30
Ortho-Clinical Vitros 42 -0.17 -0.67 42 -0.10 -0.52
Pointe Scientific HbA1c on Modular P 42 0.09 0.17 42 0.36 0.42
Roche Integra Gen2 42 -0.24 -0.40 42 -0.17 -0.06
Tinaquant on Hitachi 
917
42 -0.12 -0.37 42 -0.07 -0.15
Siemens DCA2000 42 -0.06 0.01 40 0.02 0.18
Ion-Exchange HPLC
Bio-Rad D-10 (short) 42 0.40 0.41 42 0.38 0.15
D-10 (extended) 42 -0.27 -0.62 41 -0.27 -0.70
Variant 20 -0.10 0.25 23 -2.03c -2.77c
Variant II NU 42 -0.24 -0.47 42 0.08 -0.14
Variant II Turbo 42 1.43° 1.96° 42 1.04c 1.44°
Menarini HA8160 Diabetes mode 42 -0.82c -1.14° gd -2.17c,d -1.58c,d
HA8160 TP mode 42 -0.14 -0.28 41 Not quantified
Tosoh 2.2 Plus 42 -1.20° -2.05c 42 0.24 0.03
G7 42 -1.26° — 2.12C 42 -0.09 -0.38
G8 42 -1.41° -2.42c 42 -0.12 -0.58
Other method types
CE (in-house) Analis Pace 5000 21 -0.08 -0.04 22 0.19 0.23
Diazyme Direct Enzymatic A1c 42 -0.24 -0.53 41 -0.23 -0.51
Axis-Shield Afinion 36 0.09 -0.16 37 -0.06 -0.30
Primus PDQ 21 -0.10 0.11 22 -0.02 0.23
“ Deming regression analysis was performed using the Ultra2 as the comparison method. The mean difference (%) of each of the other methods at clinical decision 
cutoffs of 6% and 9% were calculated for each Hb trait. To correct for intermethod calibration differences, the mean difference for homozygous HbA samples was 
subtracted from that calculated for samples containing HbE or HbD trait. 
b Methods used are listed in alphabetical order by manufacturer.
c Clinically significant {>0.6% or >0.9% HbA1c at 6% and 9% HbA1c, respectively) differences were found. 
d Calculated from only those samples for which an HbA1c result was quantified.
nonreportable since there is an extra peak appearing 
between the Alc and A0 peak. HbE and D trait chroma­
tograms appear in the G8 instruction manual. The 
present results confirm the manufacturer’s instruc­
tions and show that HbD trait results are accurate, 
whereas HbE trait results are not.
For the Variant no information is provided by the 
manufacturer about whether or not HbE or HbD trait 
chromatograms are acceptable or certain chromato­
graphic features are unacceptable. The present data 
show that HbE trait chromatograms are indistinguish­
able from those with HbAA; fortunately the results
from the present study also show that results from 
these chromatograms are acceptable. Our study data 
indicate that results for HbD trait are not acceptable for 
the Variant, results that are consistent with a previous 
report (12). Although not stated in the instruction 
manual for the Variant method, HbD trait samples 
showed chromatograms with “unknown” peaks, one of 
which separates between the Alc and A0 peaks (see Sup­
plemental Fig. 1 in the online Data Supplement); the 
careful technician should be able to categorize such 
chromatograms as unreportable. The instruction man­
ual for the Variant II NU states that specimen results
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showing HbE and HbD traits are acceptable and shows 
typical chromatograms from samples with HbE and 
HbD trait with both HbE and HbD appearing in the 
“E,D” window. Our results confirm that results show­
ing HbE and HbD traits are acceptable for the Variant 
IINU. The instruction manual for the Variant II Turbo 
does not mention samples with HbE or HbD traits. 
However, all HbE and HbD trait chromatograms in­
clude a peak in the “variant window” that appears on 
the printed chromatogram as a split A0 peak (see Sup­
plemental Fig. 2 in the online Data Supplement). In the 
present study, we found these results to be unaccept­
able for the Variant II Turbo. For the Bio-Rad D-10 
short program, the manufacturer makes no claim for 
HbAlc results with HbE and HbD trait samples. For 
the short program there is a peak that elutes after the 
HbA0 peak in the “Variant-window” for both HbD and 
HbE traits. For the D-10 extended program, samples 
containing HbD have a large “unknown” peak sepa­
rated after HbA2. HbE appears to be separated in the 
HbA2 window, causing a very high HbA2 value (up to 
approximately 30%). We found that results were 
within clinically acceptable limits (±10%  o f the HbAlc 
at 6% and 9%) for both the short and extended pro­
gram and that results were actually better with the short 
program.
For the Menarini HA-8160, no statement about 
HbE or HbD traits is included in the instruction man­
ual. In the diabetes mode, samples containing HbD 
trait show an extra peak in the “S/C Window” (see Sup­
plemental Fig. 3 in the online Data Supplement). In 
most cases (75%) the peaks are not labeled, no result is 
given for HbAlc, and the chromatogram indicates “ab­
normal separation” (see Supplemental Fig. 3b in the 
online Data Supplement). Approximately 25% o f HbD 
trait chromatograms do indicate a HbAlc result and the 
only distinction is the extra peak in the S/C Window 
(see Supplemental Fig. 3c in the online Data Supple­
ment). For those HbD trait samples for which a result is 
provided, the results are outside clinically acceptable 
limits. For HbE trait, there is a small extra peak on the 
trailing edge of the A0 peak that is not completely sep­
arated or identified (see Supplemental Fig. 3d in the 
online Data Supplement). The present study shows 
that HbE trait gives unreportable results for the HA- 
8160 diabetes mode. In the TP mode, HbD trait is in­
dicated by a report o f “abnormal separation,” the peaks 
are not labeled, and no HbAlc result is reported (see 
Supplemental Fig. 4 in the online Data Supplement). 
For samples with HbE, the HbE coelutes in the “A2/ 
Var” window, indicating that the A2 result is artificially 
increased; the present data show that the results for 
HbAE in the TP Mode are acceptable.
Discussion
Because HbAlc has been shown to be directly related to 
risk for diabetes complications, the HbAlc test is an 
essential tool in the management o f diabetes. World­
wide clinical diabetes guidelines recommend specific 
treatment goals related to HbAlc. Previous studies have 
shown that for some assay methods the presence of 
Hb variants such as HbS and HbC traits interferes with 
HbAlc measurement results, but few data were avail­
able regarding potential interference from HbD or 
HbE traits. HbD and HbE traits are 2 of the 4 most 
common Hb variants both in the US and worldwide. 
Because patients with these variants usually show no 
obvious clinical symptoms, physicians maybe unaware 
that their patient with diabetes has one of these variants.
None of the immunoassay, enzymatic, or boronate 
affinity methods we investigated showed clinically signif­
icant interference, whereas some of the ion-exchange 
HPLC methods showed interference from HbE or HbD 
traits, or both. All of the ion-exchange methods that dem­
onstrated interferences from HbE and/or HbD trait, with 
the exception of the Variant II Turbo, produced artifi­
cially low results. Reporting of such results could lead to 
undertreatment of hyperglycemia, with concomitant in­
creased risks for complications. In the case of the Variant 
II Turbo, the artificially increased results seen in the pres­
ence of both HbE and HbD traits could result in overly 
aggressive treatment that could increase risk of hypogly­
cemia. As mentioned previously, ion-exchange chro­
matograms must be carefully examined to identify possi­
ble interference from these Hb variants so that inaccurate 
results are not reported (13 ). In most (but not all) cases, 
reporting of inaccurate results can be avoided if manufac­
turer instructions are followed carefully. For some meth­
ods, however, manufacturer instructions alone do not 
provide sufficient information for making the correct de­
cision about reporting results. Laboratories should be 
aware of the limitations of their methods with respect to 
these variants and indicate this information on reports to 
physicians. Physicians should consider the possibility of 
interference from an Hb variant if a patient’s HbA lc result 
is significantly different from what is expected on the basis 
results of blood glucose self-monitoring and/or other di­
agnostic test results or clinical symptoms.
In addition to interference of these variant Hbs on 
the actual measurement method for HbAlc, biological 
factors that may affect HbA lc concentrations must also be 
considered. For example, altered erythrocyte lifespan or a 
variant Hb that glycates at a rate different from that of 
HbA could result in artificially low or high HbAlc. Re­
ports suggest that erythrocyte lifespan is normal in indi­
viduals with HbD trait and homozygous HbE (8, 14). 
Given that the amino acid substitutions in HbD and HbE 
are both far from the primary site of Hb glycation (the
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N-terminus of the j3 chain), it seems unlikely that either 
variant would demonstrate glycation rates that are signif­
icantly different from that of HbA. Nonetheless, further 
studies are needed to verify this assumption.
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